IN OVO VACCINATION AGAINST NEWCASTLE DISEASE

Abstract: The present invention is concerned with a vaccine for in ovo vaccination of poultry against Newcastle Disease Infections. This vaccine contains Newcastle Disease Viruses of the strain with the internal indication NDW, deposited at CNCM (Institut Pasteur) under number I-781.

Description: IN OVO VACCINATION AGAINST NEWCASTLE DISEASE The present invention is concerned with a vaccine suitable for in ovo vaccination against Newcastle Disease infection, with the use of a Newcastle Disease Virus strain in the preparation of such a vaccine, as well as with the protection of poultry against Newcastle Disease infection by in ovo vaccination with a vaccine containing a Newcastle Disease virus train. In ovo vaccination of virus-containing vaccines was extensively described by Sharma et al. (US Patent No 4458630). In particular it teaches that live Marek's disease virus can be injected into amniotic fluid within the egg, whereafter the embryo is infected and the vaccine virus replicates to a high titer which induces the formation of protective antibodies in the treated embryo. (Sharma; Avian Diseases 29, 1155, 1167- 68 (1985). In US Patent No 5427791 Ahmad et al. describe the embryonal vaccination against Newcastle Disease. Herein, in order to provide for a non-pathogenic attenuation of the live Newcastle Disease virus (strain NDV-B 1), the viruses were modified through use of ethyl methane sulfonate (EMS). A disadvantage of this type of modification is the fact that EMS is a mutagen and that the vaccine is suspected to act as a mutagen as well, which is undesirable for regular administration of the vaccine. On the other hand, untreated NDV-B 1 cannot be applied for in ovo vaccination as almost all of the embryos will die upon injection of the eggs with this unmodified virus. Furthermore, it has been found that the margin between minimum effective dose and the maximum dose for safety for these modified viruses is less than 10 (hence less than logl). For practical purposes and in view of the errors as a result of production and due to losses during storage, this margin is too small. Surprisingly it has been found that a vaccine preparation containing Newcastle Disease viruses of the strain NDW is particularly suited for in ovo application. Hence the present invention is concerned with the use of Newcastle Disease virus of the strain NDW in the in ovo vaccination of poultry. As a further embodiment the invention is concerned with the use of Newcastle Disease virus of the strain NDW in the preparation of a vaccine suitable for in ovo administration poultry. Samples of the Newcastle Disease virus strain NDW were deposited at CNCM of Institut Pasteur under No 781. See EP 351908. Advantageously, the NDW strain is administered in an amount of between 10 _1 and 10 3 and more in particular in an amount between 10 ~0 - 7 and 10 2 - 2 per egg. For obtaining the best results in immunisation it was found that the NDW containing vaccine can be administered in ovo at between 17 and 19 days of incubation, preferably at 18 days of incubation. Example 1 Preparation of NDW vaccine for in ovo administration A Working Seed Virus stock was prepared from a Master Seed Virus (deposited at CNCM, Institut Pasteur under No 1-781) by inoculation into the allantoic cavity of embryonated SPF chicken eggs. In the same way the vaccine is produced by inoculation of Working Seed Virus into the allantoic cavity of embryonated SPF eggs. After incubation the allantoic fluid containing the vaccine virus is harvested. The allantoic fluid is diluted and frozen and stored at -50°C. Before filling the allantoic fluid is thawed, further diluted until the required concentration of vaccine virus, mixed with stabiliser, filled into vials and freeze-dried. Example 2 The Safety of the in ovo NDW vaccine in SPF eggs. SPF eggs were vaccinated at 18 days of incubation in the amnion by the method described by Sharma and Burmester (Avian Diseases 26 (1), 134-149) with the vaccine described in Example 1. Six groups of eggs were vaccinated according to the scheme outlined in the following Table. Table 1: Safety of in ovo vaccination of SPF eggs with NDW vaccine Conclusion: In ovo vaccination of SPF eggs at 18 days of embryonal development with NDV vaccine is safe with a maximum dose of between 10 1 - 2 and 10 2 - 2 EID50 per egg. Example 3 The safety of the in ovo NDW vaccine in commercial broiler eggs with maternal antibodies. Commercial broiler eggs having maternal antibodies were vaccinated at 18 days of incubation in the amnion by the method described by Sharma and Burmester (Avian Diseases 26 (1), 134-149) with the vaccine described in Example 1. Eight groups of eggs were vaccinated according to the scheme outlined in the following Table. Table 2: Safety of in ovo vaccination of commercial broiler eggs with NDW vaccine Conclusion: In ovo vaccination of broiler eggs with maternal antibodies is safe (no effect on hatching) up to a dose of at least 10 2 EID50 per egg. Example 4 Efficacy of in ovo vaccination of SPF eggs with NDV vaccine The efficacy of NDV vaccine prepared according to Example 1 was examined in SPF eggs. Parameters for the protection were the antibody response after vaccination (haemagglutination inhibition test = HI test) and percentage of mortality after challenge. The challenge virus was the strain Hertz 33/56 of Newcastle Disease Virus, with was administered to each of the chickens in an amount of 10 5 0 EID50. Five groups of eggs were vaccinated according to the scheme outlined in the table below: Conclusion: In ovo vaccination of SPF eggs at 18 days of embryonal development with NDV vaccine is effective. A vaccine dose of about 10 * °- 7 per egg is the minimal effective dose for in ovo NDV vaccination. Example 5 Efficacy of in ovo vaccination with NDV vaccine of commercial broiler eggs with maternal antibodies. The efficacy of the NDV vaccine prepared according to Example 1 was examined in commercial broiler eggs with maternal antibodies (HI titer of 5.1 at one day of age). Parameters for the protection were the antibody response after vaccination (HI test) and percentage of mortality after challenge. The challenge virus was the strain Hertz 33/56 of Newcastle Disease Virus, which was administered to each of the chickens in an amount of 10 5 0 EID 5 o. Three groups of eggs were vaccinated according to the scheme outlined in the table below: Table 4: Efficacy of in ovo vaccination in commercial broiler eggs Conclusion: In ovo vaccination with NDV vaccine of commercial broiler eggs at 18 days of embryonal development is effective. This is not influenced by the presence of maternal antibodies.

Claims: CLAIMS: 1. A vaccine for in ovo vaccination of poultry against Newcastle Disease infections, characterised in that it comprises a virus having the characteristics of the strain NDW, an example of which is deposited at CNCM (Institut Pasteur) under number 1-781. 2. A vaccine according to Claim 1 characterised in that the viruses of strain NDW are administered in an amount of between 1O -1 and 10 3 EID50 per egg. 3. A vaccine according to Claim 1 characterised in that the viruses of strain NDW are administered in an amount of between 10 -0 - 7 and 10 2 - 2 EID50 per egg. 4. A vaccine according to Claim 1 characterised in that the viruses of strain NDW are administered in ovo at between 17 and 19 days of incubation. 5. A vaccine according to Claim 1 characterised in that the viruses of strain NDW are administered in ovo at 18 days of incubation. 6. Use of a Newcastle Disease Virus strain NDW, deposited at CNCM (Institut Pasteur) under number 1-781, in the preparation of a vaccine suitable for in ovo vaccination. 7. A use according to Claim 6, characterised in that the viruses of strain NDW are present in an amount of between 1O -1 and 10 3 per egg. 8. Use according to Claim 6, characterised in that the viruses of strain NDW are present in an amount of between lO -0 - 7 and 10 2 - 2 per egg. 9. A method for preventing or treating Newcastle Disease infections in poultry comprising in ovo administration of a vaccine comprising a virus having the characteristics of the strain NDW an example of which is deposited at CNCM (Institut Pasteur) under number 1-781.

Inventors: DAVELAAR FRANS GERRIT, DAVELAAR, FRANS, GERRIT
Applicants: DAVELAAR FRANS GERRIT, DIMMINACO AG, DAVELAAR, FRANS, GERRIT
Application year: 1997
Main classification: A61K39
IPC codes: A61K39, A61P31